EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
Rhea-AI Summary
EDAP (Nasdaq: EDAP) will release fourth quarter and full year 2025 financial results before market open on Wednesday, March 25, 2026.
The company will host a conference call and webcast on March 25 at 8:30 a.m. EDT featuring CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch. Dial-in and webcast registration details are provided.
Positive
- None.
Negative
- None.
Market Reaction – EDAP
Following this news, EDAP has gained 7.02%, reflecting a notable positive market reaction. The stock is currently trading at $4.27. This price movement has added approximately $10M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Healthcare/Medical Distribution peers showed mixed moves, with QIPT up 1.11%, OMI up 2.19%, YI modestly up 0.26%, while ZYXI fell 37.34% and COSM declined 5.94%. Momentum scanner only flagged BDMD up 2.41%, suggesting stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Board changes | Neutral | -2.6% | Board refresh with new director appointment and one resignation. |
| Jan 12 | Prelim 2025 results | Positive | +11.4% | Record Q4 and full-year 2025 HIFU revenue and 2026 guidance. |
| Nov 20 | Regulatory clearance | Positive | +5.8% | FDA 510(k) clearance for upgraded Focal One HIFU imaging and workflow. |
| Nov 18 | Conference appearance | Neutral | +3.4% | Participation in Piper Sandler healthcare conference with investor meetings. |
| Nov 06 | Q3 2025 earnings | Positive | -4.3% | Q3 revenue growth, stronger HIFU segment, improved margin, narrower loss. |
Positive operational or regulatory news has often seen supportive price reactions, while detailed earnings reports have twice coincided with negative moves.
Over the last several months, EDAP reported multiple milestones. On Nov 6, 2025, Q3 2025 results showed revenue growth and margin improvement but the stock fell. Later, a Nov 20, 2025 FDA 510(k) clearance and a conference appearance in late November both saw positive reactions. Preliminary record Q4/full-year 2025 HIFU revenue and 2026 guidance on Jan 12, 2026 also drew a strong gain. The upcoming Mar 25, 2026 earnings date will finalize those preliminary figures.
Market Pulse Summary
The stock is up +7.0% following this news. A strong positive reaction aligns with prior responses to constructive updates, such as the Jan 12, 2026 preliminary 2025 figures that saw a notable gain. Investors had already received high-level revenue and guidance metrics, so enthusiasm could reflect confidence that final audited results will confirm that trajectory. However, past instances where detailed earnings led to negative moves suggest that valuation and expectations sensitivity remained a risk factor.
AI-generated analysis. Not financial advice.
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT
AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
Date: Wednesday, March 25th
Time: 8:30 a.m. EDT
Domestic: 1-800-579-2543
International: 1-785-424-1789
Passcode: EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1751611&tp_key=27ba007fb5
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and the United States as a leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.
Investor Contacts
Investor Relations
EDAP TMS SA
investor.relations@focalone.com
FAQ
When will EDAP (EDAP) announce its Q4 and full year 2025 results?
How can investors join EDAP's March 25, 2026 earnings conference call?
Where can I watch the EDAP (EDAP) March 25, 2026 webcast?
Who will present on EDAP's March 25, 2026 earnings call?
What time is EDAP's conference call for the full year 2025 results on March 25, 2026?
